HER2 testing in gastric and gastroesophageal junction adenocarcinoma determines whether the tumor overexpresses HER2 protein or has ERBB2 gene amplification strongly enough to qualify for HER2-directed therapy. Testing usually starts with immunohistochemistry (IHC). An IHC score of 3+ is positive, 0 or 1+ is negative for standard HER2-positive treatment pathways, and 2+ is equivocal and generally requires in-situ hybridization such as FISH or dual ISH. Gastric HER2 scoring differs from breast scoring because staining can be incomplete and basolateral, and because tumors often show marked heterogeneity. Adequate biopsy sampling is therefore essential. HER2 status is now relevant at first diagnosis of advanced disease, and treatment options expanded again in August 2026 with FDA-approved zanidatamab-based first-line regimens under defined IHC/ISH criteria. A useful HER2 report should state the IHC score, amplification result when needed, specimen, assay, and enough detail to match a current treatment label.
- Gastric HER2 testing is tumor-based and usually begins with IHC using gastric-specific scoring.
- IHC 3+ is positive; IHC 2+ is equivocal and generally needs ISH/FISH confirmation of ERBB2 amplification.
- Heterogeneous HER2 expression is common, so multiple viable biopsy fragments improve reliability.
- HER2-positive advanced gastric/GEJ cancer has multiple HER2-directed treatment options, with exact eligibility tied to the regimen and assay.
- A new metastatic specimen may be worth retesting if an older negative result conflicts with the current clinical picture.
Table of Contents
- What the gastric HER2 test measures
- How gastric IHC scoring differs from breast scoring
- What FISH or other ISH adds
- What a positive result means for treatment
- Negative results, heterogeneity, and retesting
- What to look for on the HER2 report
- Practical next steps after gastric HER2 testing
What the gastric HER2 test measures
HER2 is a membrane receptor encoded by ERBB2. Immunohistochemistry measures the amount and pattern of HER2 protein on tumor-cell membranes. In-situ hybridization measures whether ERBB2 gene copies are increased. Amplification usually drives high protein expression, but the two tests answer different analytical questions.
The most clinically important result is whether the tumor meets the HER2 definition used for a specific therapy. That definition historically centered on IHC 3+ or IHC 2+ with ISH positivity for trastuzumab-based therapy. Newer regimens may use more specific categories, so the numeric IHC score should be preserved.
How gastric IHC scoring differs from breast scoring
Gastric adenocarcinoma often shows lateral or basolateral membranous staining rather than complete circumferential staining. Clusters of strongly staining cells can also be focal. For biopsy specimens, the number and cohesiveness of positive tumor cells are important; for resection specimens, the percentage of positive tumor area is assessed.
This biology is why a breast-style mental model can produce errors. Pathologists use gastroesophageal-specific criteria, and equivocal IHC 2+ cases move to ISH. The report should not be reduced to “HER2 positive” without retaining the underlying score because an IHC 3+ tumor and an IHC 2+/ISH+ tumor may qualify differently under newer labels.
What FISH or other ISH adds
FISH and dual-color ISH visualize ERBB2 gene signals within tumor-cell nuclei, often compared with a chromosome 17 reference probe. The test is mainly used to resolve IHC 2+ cases. A clearly amplified tumor supports HER2-driven biology even when protein staining is not uniformly strong.
Technical quality matters. Areas selected for counting should contain invasive tumor, not benign glands, necrosis, or in-situ change. Heterogeneity may require counting more than one area. If IHC and ISH appear discordant, pathology review can determine whether the discrepancy reflects sampling, borderline amplification, or technical limitations.
What a positive result means for treatment
HER2-positive advanced gastric or GEJ adenocarcinoma has long been treated with trastuzumab-containing first-line regimens in appropriate patients, with additional HER2-directed options available later. In August 2026, the FDA approved zanidatamab-hrii with chemotherapy and tislelizumab-jsgr for HER2-positive IHC 3+ or IHC 2+/ISH+ unresectable locally advanced or metastatic gastroesophageal adenocarcinoma, and also a zanidatamab-plus-chemotherapy regimen for the IHC 3+ subgroup.
Those distinctions show why the exact IHC/ISH category matters. Treatment also depends on PD-L1, MSI/dMMR, CLDN18.2, disease burden, prior therapy, and patient fitness. HER2 is a gatekeeper biomarker, not the entire treatment plan.
Negative results, heterogeneity, and retesting
No biomarker works in isolation. A technically accurate result can still be clinically misleading if it is applied to the wrong cancer type, disease stage, specimen, or treatment question. Cutoffs may also differ by assay, drug label, guideline, and country. For that reason, the laboratory’s own interpretive criteria and the treating team’s current guideline should take priority over a generic internet threshold.
Tumors are heterogeneous, meaning different areas can carry different alterations or levels of protein expression. A small biopsy may miss a positive clone, while a blood-based assay can miss disease that sheds little DNA into the circulation. Conversely, a detectable alteration may be real but not be the main driver of the current disease. Pre-analytic issues such as delayed fixation, decalcification, low tumor content, recent transfusion, or poor plasma handling can also affect some assays.
The safest interpretation separates three questions: analytical validity—did the assay measure what it claims to measure; clinical validity—does the result correlate with the cancer feature of interest; and clinical utility—does acting on the result improve a meaningful decision for this patient. A result can be strong in one category and limited in another.
HER2 expression can also change between the primary tumor and metastases or after HER2-directed treatment. Retesting is most reasonable when the original sample was limited, the disease has recurred after a long interval, or a new biopsy is already being obtained for clinical reasons.
What to look for on the HER2 report
Confirm the specimen site and date, IHC antibody/assay, IHC score, and whether ISH was performed. For an equivocal case, the ISH interpretation should be explicit. For a positive case, note whether it is IHC 3+ or IHC 2+/ISH+, because current therapies can distinguish these categories.
Also check for comments about heterogeneity or limited tumor. If the biopsy had only a few viable fragments and was negative, ask whether sampling was adequate. A pathology review at a center experienced in gastroesophageal HER2 scoring can be useful when a high-stakes treatment decision rests on a borderline result.
Practical next steps after gastric HER2 testing
A biomarker result should be read beside the pathology report, stage, imaging, treatment history, and the exact specimen tested. A useful question for the oncology team is not simply “is this positive?” but “what decision does this result change now?” That keeps the result tied to a concrete action such as confirming a diagnosis, choosing a drug, deciding whether hereditary evaluation is needed, or setting a surveillance plan.
If a result seems inconsistent with the clinical picture, ask whether the sample had enough viable tumor, whether the method covered the relevant alteration, and whether a newer metastatic or recurrent specimen would be more representative. Repeating a test is most useful when there is a specific reason to think the original specimen was inadequate, old, or biologically different from the disease being treated today.
Patients should also keep a copy of the complete molecular or pathology report, not only a portal summary. The full report usually lists the method, specimen, tumor percentage, assay limitations, exact variant or staining score, and interpretive comments. Those details matter when seeking a second opinion, transferring care, or checking eligibility for a targeted therapy or clinical trial.
One practical way to avoid overreading HER2 Test for Gastric Cancer is to separate the laboratory finding from the clinical decision. The report may be analytically clear while the next step remains conditional on stage, prior therapy, other biomarkers, and patient goals. For example, a result that is highly relevant in metastatic disease may have no established treatment role after curative surgery. Likewise, a biomarker that predicts drug resistance is not necessarily a marker of worse overall prognosis. Keeping those categories separate makes the report easier to use and prevents a single word such as “positive” from carrying more meaning than the evidence supports.
The specimen date deserves attention. Cancer evolves under treatment, and the sample used for HER2 Test for Gastric Cancer may have been collected months or years before the current decision. Early driver alterations often remain stable, but protein expression, copy number, and acquired resistance mechanisms can change. Retesting is most valuable when there is a plausible biological reason for change and when a new result could alter management. Repeating testing merely because a value is available is less useful than choosing the specimen that best represents the disease being treated now.
Laboratory reports also vary in how much interpretation they provide. Some give only a final category; others show raw staining percentages, copy-number estimates, variant allele fractions, quality metrics, and assay limitations. For HER2 Test for Gastric Cancer, the detailed version is preferable because treatment criteria can evolve. A result that was not actionable when the tissue was first tested may become relevant later, and the original numerical or molecular detail may allow the oncology team to reassess eligibility without immediately repeating a biopsy.
Finally, biomarker testing works best as part of multidisciplinary care. Pathologists judge specimen quality and assay interpretation; medical oncologists connect the finding to treatment; surgeons and gastroenterologists provide disease context; genetic counselors address possible inherited risk when appropriate. Patients do not need to master every technical detail, but they benefit from knowing the purpose of the test, the exact result, what uncertainty remains, and what concrete decision follows. Those four questions turn a complex biomarker report into a usable plan.
One practical way to avoid overreading HER2 Test for Gastric Cancer is to separate the laboratory finding from the clinical decision. The report may be analytically clear while the next step remains conditional on stage, prior therapy, other biomarkers, and patient goals. For example, a result that is highly relevant in metastatic disease may have no established treatment role after curative surgery. Likewise, a biomarker that predicts drug resistance is not necessarily a marker of worse overall prognosis. Keeping those categories separate makes the report easier to use and prevents a single word such as “positive” from carrying more meaning than the evidence supports.
The specimen date deserves attention. Cancer evolves under treatment, and the sample used for HER2 Test for Gastric Cancer may have been collected months or years before the current decision. Early driver alterations often remain stable, but protein expression, copy number, and acquired resistance mechanisms can change. Retesting is most valuable when there is a plausible biological reason for change and when a new result could alter management. Repeating testing merely because a value is available is less useful than choosing the specimen that best represents the disease being treated now.
Laboratory reports also vary in how much interpretation they provide. Some give only a final category; others show raw staining percentages, copy-number estimates, variant allele fractions, quality metrics, and assay limitations. For HER2 Test for Gastric Cancer, the detailed version is preferable because treatment criteria can evolve. A result that was not actionable when the tissue was first tested may become relevant later, and the original numerical or molecular detail may allow the oncology team to reassess eligibility without immediately repeating a biopsy.
Finally, biomarker testing works best as part of multidisciplinary care. Pathologists judge specimen quality and assay interpretation; medical oncologists connect the finding to treatment; surgeons and gastroenterologists provide disease context; genetic counselors address possible inherited risk when appropriate. Patients do not need to master every technical detail, but they benefit from knowing the purpose of the test, the exact result, what uncertainty remains, and what concrete decision follows. Those four questions turn a complex biomarker report into a usable plan.
One practical way to avoid overreading HER2 Test for Gastric Cancer is to separate the laboratory finding from the clinical decision. The report may be analytically clear while the next step remains conditional on stage, prior therapy, other biomarkers, and patient goals. For example, a result that is highly relevant in metastatic disease may have no established treatment role after curative surgery. Likewise, a biomarker that predicts drug resistance is not necessarily a marker of worse overall prognosis. Keeping those categories separate makes the report easier to use and prevents a single word such as “positive” from carrying more meaning than the evidence supports.
The specimen date deserves attention. Cancer evolves under treatment, and the sample used for HER2 Test for Gastric Cancer may have been collected months or years before the current decision. Early driver alterations often remain stable, but protein expression, copy number, and acquired resistance mechanisms can change. Retesting is most valuable when there is a plausible biological reason for change and when a new result could alter management. Repeating testing merely because a value is available is less useful than choosing the specimen that best represents the disease being treated now.
Laboratory reports also vary in how much interpretation they provide. Some give only a final category; others show raw staining percentages, copy-number estimates, variant allele fractions, quality metrics, and assay limitations. For HER2 Test for Gastric Cancer, the detailed version is preferable because treatment criteria can evolve. A result that was not actionable when the tissue was first tested may become relevant later, and the original numerical or molecular detail may allow the oncology team to reassess eligibility without immediately repeating a biopsy.
Finally, biomarker testing works best as part of multidisciplinary care. Pathologists judge specimen quality and assay interpretation; medical oncologists connect the finding to treatment; surgeons and gastroenterologists provide disease context; genetic counselors address possible inherited risk when appropriate. Patients do not need to master every technical detail, but they benefit from knowing the purpose of the test, the exact result, what uncertainty remains, and what concrete decision follows. Those four questions turn a complex biomarker report into a usable plan.
One practical way to avoid overreading HER2 Test for Gastric Cancer is to separate the laboratory finding from the clinical decision. The report may be analytically clear while the next step remains conditional on stage, prior therapy, other biomarkers, and patient goals. For example, a result that is highly relevant in metastatic disease may have no established treatment role after curative surgery. Likewise, a biomarker that predicts drug resistance is not necessarily a marker of worse overall prognosis. Keeping those categories separate makes the report easier to use and prevents a single word such as “positive” from carrying more meaning than the evidence supports.
The specimen date deserves attention. Cancer evolves under treatment, and the sample used for HER2 Test for Gastric Cancer may have been collected months or years before the current decision. Early driver alterations often remain stable, but protein expression, copy number, and acquired resistance mechanisms can change. Retesting is most valuable when there is a plausible biological reason for change and when a new result could alter management. Repeating testing merely because a value is available is less useful than choosing the specimen that best represents the disease being treated now.
Laboratory reports also vary in how much interpretation they provide. Some give only a final category; others show raw staining percentages, copy-number estimates, variant allele fractions, quality metrics, and assay limitations. For HER2 Test for Gastric Cancer, the detailed version is preferable because treatment criteria can evolve. A result that was not actionable when the tissue was first tested may become relevant later, and the original numerical or molecular detail may allow the oncology team to reassess eligibility without immediately repeating a biopsy.
References
- Korean Practice Guidelines for Gastric Cancer 2024: An Evidence-based, Multidisciplinary Approach (Update of 2022 Guideline) 2025 (Guideline)
- SEOM-GEMCAD-TTD clinical guideline for the diagnosis and treatment of gastric cancer (2023) 2024 (Guideline)
- Novel Biomarkers of Gastric Cancer: Current Research and Future Perspectives 2023 (Review)
- FDA approves zolbetuximab-clzb with chemotherapy for gastric or gastroesophageal junction adenocarcinoma 2024 (Official)
- FDA approves zanidatamab-hrii and tislelizumab-jsgr for HER2-positive gastric, gastroesophageal junction, or esophageal adenocarcinoma 2026 (Official)
Disclaimer
This article explains biomarker testing for educational purposes and is not a diagnosis or treatment plan. Cancer testing and treatment should be interpreted by the oncology and pathology teams using the complete medical record, current guidelines, and the specific laboratory method. Seek prompt medical care for new or rapidly worsening symptoms rather than relying on a biomarker result alone.
